Heterocyclic compounds as immunomodulators

1. A compound of Formula (IIc-4):

or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:

the subscript r is an integer of 1, 2 or 3;

R 3 is methyl or halo;

R 5 is C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 haloalkoxy, CN, halo, or OH;

each R 6 is independently selected from H, halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, CN, OR a , C(O)R a , C(O)NR a R a , C(O)OR a , NHR a , NR a R a , and NR a C(O)R a , wherein the C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl of R 6 are each optionally substituted with 1 or 2 R b substituents;

R 7 is H, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 haloalkoxy, CN, halo, or OH;

R 10 and R 11 are each independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, —C(O)R g , —C(O)OR g , and —C(O)NR g R g , wherein the C 1-6 alkyl and C 1-6 haloalkyl of R 10 or R 11 are each optionally substituted with 1, 2 or 3 independently selected R f substituents;

or R 10 and R 11 taken together with the nitrogen atom to which they are attached form 4-, 5-, 6- or 7-membered heterocycloalkyl, wherein the 4-, 5-, 6- or 7-membered heterocycloalkyl is optionally substituted with 1 or 2 R h substituents;

each R 13 is independently H, C 1-6 haloalkyl or C 1-6 alkyl optionally substituted with a substituent selected from C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 haloalkoxy, CN, halo, or OH;

each R a is independently selected from H, CN, C 1-6 alkyl, C 1-4 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl of R a are each optionally substituted with 1 or 2 R d substituents;

each R d is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, halo, CN, NH 2 , OR e , C(O)R e , C(O)NR e R e , C(O)OR e , NHR e , NR e R e , and NR e C(O)R e ;

each R e is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl;

each R b substituent is independently selected from halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C 1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, CN, OH, NH 2 , OR c , C(O)R c , C(O)NR c R c , C(O)OR c , NHR c , NR c R c , and NR c C(O)R c ; wherein the C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 haloalkoxy, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, (5-10 membered heteroaryl)-C 1-4 alkyl- and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of R b are each further optionally substituted with 1 or 2 independently selected R d substituents;

each R c is independently selected from H, C 1-6 alkyl, C 1-4 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl of R c are each optionally substituted with 1, 2, or 3 R f substituents;

each R f is independently selected from C 1-4 alkyl, C 1-4 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, halo, CN, OR g , C(O)R g , C(O)NR g R g , C(O)OR g , NHR g , NR g R g , and NR g C(O)R g ;

each R g is independently selected from H, C 1-6 alkyl, C 1-4 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl;

each R h is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, halo, CN, OR i , C(O)R i , C(O)NR i R i , C(O)OR i , NR i R i , and NR i C(O)R i ; and

each R i is independently selected from H, C 1-4 alkyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-4 alkenyl, and C 2-4 alkynyl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R 13 is H.

3. The compound of claim 1 , or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R 6 is (3-hydroxypyrrolidin-1-yl)methyl, (R)-(3-hydroxypyrrolidin-1-yl)methyl, or (S)-(3-hydroxypyrrolidin-1-yl).

4. The compound of claim 1 , or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R 5 is halo or C 1-4 alkyl.

5. The compound of claim 1 , or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R 5 is halo, methyl or CN.

6. The compound of claim 1 , or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R 3 is methyl or Cl.

7. The compound of claim 1 , or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein NR 10 R 11 is 3-carboxypyrrolidin-1-yl, (R)-3-carboxypyrrolidin-1-yl, or (S)-3-carboxypyrrolidin-1-yl.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R 6 is independently selected from C 1-6 alkyl, which is optionally substituted with 1 or 2 R b substituents.

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the subscript r is an integer of 1.

10. The compound of claim 5 , or a pharmaceutically acceptable salt thereof, wherein R 3 is methyl.

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is CN.

12. The compound of claim 10 , or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R 13 is H.

13. The compound of claim 12 , or a pharmaceutically acceptable salt thereof, wherein the subscript r is an integer of 1.

14. The compound of claim 13 , or a pharmaceutically acceptable salt thereof, wherein R 7 is CN.

15. The compound of claim 14 , or a pharmaceutically acceptable salt thereof, wherein each R 6 is independently selected from C 1-6 alkyl, which is optionally substituted with 1 or 2 R b substituents.

16. The compound of claim 14 , or a pharmaceutically acceptable salt thereof, wherein each R 6 is (3-hydroxypyrrolidin-1-yl)methyl, (R)-(3-hydroxypyrrolidin-1-yl)methyl, or (S)-(3-hydroxypyrrolidin-1-yl).

17. The compound of claim 14 , or a pharmaceutically acceptable salt thereof, wherein —NR 10 R 11 is 3-carboxypyrrolidin-1-yl, (R)-3-carboxypyrrolidin-1-yl, or (S)-3-carboxypyrrolidin-1-yl.

18. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt or a stereoisomer thereof, and one or more pharmaceutically acceptable excipient or carrier.